伴有TP53突变和BCR/ABL1的急性红系白血病：分类与管理中的挑战 - Suppr | 超能文献

相似文献

1

Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management.伴有TP53突变和BCR/ABL1的急性红系白血病：分类与管理中的挑战

Ann Hematol. 2024 Mar;103(3):1013-1014. doi: 10.1007/s00277-023-05561-3. Epub 2023 Nov 29.

2

BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?慢性髓性白血病中的BCR-ABL1突变筛查：下一个会是现在吗？

Lancet Haematol. 2019 May;6(5):e236-e237. doi: 10.1016/S2352-3026(19)30046-8.

3

The first report of chronic myelogenous leukemia with e19a2 micro-BCR/ABL1 presenting with massive myelofibrosis.首例伴有大量骨髓纤维化的e19a2微小BCR/ABL1慢性粒细胞白血病报告。

Blood Cells Mol Dis. 2017 Jun;65:68-70. doi: 10.1016/j.bcmd.2017.05.001. Epub 2017 May 3.

4

Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.找到合适的 BCR-ABL1 酪氨酸激酶抑制剂：使用尼洛替尼成功治疗携带 V299L 突变的慢性髓性白血病患者的病例报告。

BMC Cancer. 2018 Nov 12;18(1):1097. doi: 10.1186/s12885-018-5004-3.

5

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.慢性髓性白血病中导致伊马替尼耐药的BCR-ABL1激酶结构域突变的检测

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

6

Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.慢性髓性白血病中BCR-ABL1激酶结构域突变的反射性筛查

Clin Lab. 2016;62(5):975-6. doi: 10.7754/clin.lab.2015.150938.

7

Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.伴有新型e8a1 BCR-ABL1融合的慢性髓性白血病：尼洛替尼治疗后的快速分子反应

Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1281413. Epub 2017 Jan 25.

8

Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.一名慢性髓性白血病患者中BCR-ABL1融合序列的异常定位。

Hematology. 2012 Nov;17(6):321-4. doi: 10.1179/1607845412Y.0000000012. Epub 2012 Sep 14.

9

CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.伴有CALR突变和BCR-ABL1融合基因的CALR突变型原发性骨髓纤维化演变为慢性髓性白血病

Ann Hematol. 2016 Dec;95(12):2101-2104. doi: 10.1007/s00277-016-2827-3. Epub 2016 Oct 3.

10

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.阿昔替尼的极端突变选择性限制了其作为BCR-ABL1阳性白血病靶向治疗药物的潜在用途。

Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19.

本文引用的文献

1

Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases.纯（急性）红细胞白血病：41 例 Mayo 诊所病例的形态学、免疫表型、细胞遗传学、突变、治疗细节和生存数据。

Blood Cancer J. 2022 Nov 2;12(11):147. doi: 10.1038/s41408-022-00746-x.

2

Targeting -Mutated Acute Myeloid Leukemia: Research and Clinical Developments.靶向突变型急性髓系白血病：研究与临床进展

Onco Targets Ther. 2022 Apr 21;15:423-436. doi: 10.2147/OTT.S265637. eCollection 2022.

3

acute myeloid leukemia: are we always dealing with a high-risk disease?